KdT Ventures, an early stage venture firm with a focus on the integration of technology and science, has raised $3.5 million in a venture capital fund, according to a filing with the Securities and Exchange Commission.

The money was raised from 22 investors, according to the filing. The firm is seeking to raise a total of $30 million for the fund.

Established in June, KdT Ventures was founded on the principle that advances in technology are allowing mankind to solve problems that were never before addressable. KdT’s overarching goal is to help entrepreneurs turn their own ideas and visions into successful companies through funding and hands-on company development.

The Black Mountain, North Carolina-based company’s main areas of investment include cloud and synthetic biology, computational medicine and digital diagnostics.

Cain McClary is the founder and Managing Partner of KdT Ventures. Over the past 10 years, McClary has been at the forefront of the intersection between technology and science/medicine. In addition to personal investments, including companies such as Firefly Bioworks, Concert Genetics, and PathAI, McClary has been an active advisor to both companies and institutional investors.

Prior to founding KdT, McClary was the lead pathologist, analytics and data science clinical thought leader, and staff physician for Grand Rounds, a San Francisco-based digital health company focused on objectively quantifying physician quality for large self-insured employers.

During his time at Grand Rounds, McClary developed the pathology program to support over 2 million lives, negotiated several high-impact academic and employer relationships, and helped to lead the training team for all onboarding physicians.

Companies relying on a Reg D exemption do not have to register their offering of securities with the SEC, but they must file what’s known as a Form D electronically with the SEC after they first sell their securities.